Ulcerative Colitis Market to Advance at Moderate CAGR During the Forecast Period (2023-32) - Estimates DelveInsight | Key Companies - Pfizer, AbbVie, Eli Lilly, Arena Pharmaceuticals, Janssen (Johnson & Johnson), Reistone Biopharma, Landos Biopharma

DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Ulcerative Colitis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Ulcerative Colitis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Ulcerative Colitis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Ulcerative Colitis: An Overview
Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. The exact cause of IBD is unknown, but it is the result of a defective immune system.

Two major types of IBD are Ulcerative Colitis (UC) and Crohn's Disease (CD). UC is limited to the colon or large intestine. CD, on the other hand, can involve any part of the gastrointestinal tract from the mouth to the anus. Approximately 10% of cases of IBD exhibit the features of both CD and UC. These are typically known as Indeterminate Colitis (IC).

There are different types of UC, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis and Extensive Colitis.

Symptoms of UC can range from mild to extreme and vary from individual to individual. They can also change over time, when the symptoms are troublesome, with periods of recovery where a person has good health and no symptoms, alternating with relapses or flare-ups.

Ulcerative Colitis Market Key Facts
• The Ulcerative Colitis Market size was ~USD 6,900 million in 2022, which is expected to grow by 2032.
• As per DelveInsight, the Ulcerative Colitis Market is anticipated to evolve immensely in the coming years owing to the rise in healthcare spending across the world, the launch of new therapies, and the increase in the number of cases of Ulcerative Colitis.
• The total diagnosed cases of Ulcerative Colitis in the 7MM were 1,615,100 in 2022.
• The total prevalent population of Ulcerative Colitis in the 7MM in 2022 was 2,223,000. These cases are expected to rise by 2032.
• In EU4 and the UK, in 2022, there were a total of ~1,024,000 prevalent cases and 740,000 diagnosed prevalent cases of Ulcerative Colitis.
• In the 7MM, 45% mild and 55% moderate-to-severe cases of Ulcerative Colitis were observed in 2022.
• In the 7MM, the United States reported the highest prevalent cases of Ulcerative Colitis, i.e., 1,026,000 which accounted for nearly 46% of the total 7MM cases, in the year 2022.

Get a Detailed Overview of the Evolving Ulcerative Colitis Market Trends @
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Ulcerative Colitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Ulcerative Colitis therapies in the market. It also provides a detailed assessment of the Ulcerative Colitis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete details of the market trend for each marketed Ulcerative Colitis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How the Ulcerative Colitis Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Ulcerative Colitis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Ulcerative Colitis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Ulcerative Colitis Epidemiology Segmented as -
• Total Prevalent Cases of Ulcerative Colitis
• Severity-specific Cases of Ulcerative Colitis
• Total Diagnosed Cases of Ulcerative Colitis
• Age-specific Cases of Ulcerative Colitis

Get Key Insights Into the Evolving Ulcerative Colitis Epidemiology Trends @
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to be launched during the study period. The analysis covers the market share by Ulcerative Colitis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Ulcerative Colitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities in the Ulcerative Colitis Market @
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Ulcerative Colitis Therapeutics Assessment
Previously, the treatment goal for UC was to achieve clinical remission, however in the past few years the focus has now shifted to the induction of mucosal healing. For decades, mucosal healing was equated with endoscopic healing. The most significant shift is that histology has been included in the definition of mucosal healing for few years. As a result, mucosal healing now is generally defined as endoscopic plus histologic healing. Several companies are also shifting their focus towards mucosal healing.

Leading Companies in the Ulcerative Colitis Therapeutics Market Include
Some of the key companies in the Ulcerative Colitis Market include Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, Prometheus Biosciences, PNB Vesper Life Science, Pandion Therapeutics, Palatin Technologies, Theravance Biopharma, VHsquared, Seres Therapeutics, Hoffmann-La Roche, Provention Bio, Bacainn Therapeutics, Landos Biopharma, Bristol-Myers Squibb, Janssen Research & Development, GlaxoSmithKline, Assembly Biosciences, NuBiyota, and many others.

Emerging and Marketed Ulcerative Colitis Therapies Covered in the Report Include
• Etrasimod: Pfizer
• Skyrizi (Risankizumab): AbbVie
• Mirikizumab (LY-3074828): Eli Lilly and Company
• Etrasimod: Arena Pharmaceuticals
• Tremfya (Guselkumab): Janssen (Johnson & Johnson)
• SHR0302: Reistone Biopharma
• BT-11: Landos Biopharma
And Many More

Learn More About the Emerging Therapies and key Companies in the Ulcerative Colitis Therapeutics Market @
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Ulcerative Colitis Competitive Intelligence Analysis
4. Ulcerative Colitis Market Overview at a Glance
5. Ulcerative Colitis Background and Overview
6. Ulcerative Colitis Patient Journey
7. Ulcerative Colitis Epidemiology and Patient Population
8. Ulcerative Colitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Ulcerative Colitis Unmet Needs
10. Key Endpoints of Ulcerative Colitis Treatment
11. Ulcerative Colitis Marketed Products
12. Ulcerative Colitis Emerging Therapies
13. Ulcerative Colitis Seven Major Market Analysis
14. Attribute Analysis
15. Ulcerative Colitis Market Outlook (7 major markets)
16. Ulcerative Colitis Access and Reimbursement Overview
17. KOL Views on the Ulcerative Colitis Market.
18. Ulcerative Colitis Market Drivers
19. Ulcerative Colitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.